Eisai Expands into Canada
Establishes New Subsidiary to Market Products to Patients
May 10, 2010 09:03 AM Eastern Daylight Time
WOODCLIFF LAKE, N.J.--(EON: Enhanced Online News)--Eisai Inc. (Headquarters: Woodcliff Lake, NJ;
Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and
CEO: Haruo Naito) today announces the establishment of Eisai Limited in Canada, the world’s ninth largest
pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga,
Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.
“Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North
America as we prepare for future expansion in this region,” said Hajime Shimizu, Chairman and CEO, Eisai Inc.
“Most importantly, this new subsidiary will enable Eisai to introduce many of its first-in-class products to people
living in Canada who currently do not have access to these treatments, further supporting Eisai’s human health care
(hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide.”
Eisai Limited is working with Health Canada on the approval of select products from the Eisai Inc. portfolio to be
introduced in the Canadian market. Over time, additional medicines from Eisai’s portfolio of currently marketed
products may be introduced to the Canadian market as well as future products from Eisai’s pipeline. The company’s
areas of commercial focus will include neurology, gastrointestinal disorders and oncology/critical care.
Eisai Inc.
Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail
sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become
a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately
$3.